CTLA4 and neoplasm: Ipilimumab, nivolumab, and pembrolizumab are immune checkpoint inhibitors that improve tumor killing by inhibiting dendritic cells and tumor antigen ligands from attaching to CTLA-4 and PD-1 receptors, respectively.[124] As a result, the T-cell destruction of tumor cells is activated and increased.